WO2005099705A3 - Preparation of imidazole derivatives and methods of use - Google Patents

Preparation of imidazole derivatives and methods of use Download PDF

Info

Publication number
WO2005099705A3
WO2005099705A3 PCT/US2005/008904 US2005008904W WO2005099705A3 WO 2005099705 A3 WO2005099705 A3 WO 2005099705A3 US 2005008904 W US2005008904 W US 2005008904W WO 2005099705 A3 WO2005099705 A3 WO 2005099705A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
methods
imidazole derivatives
useful
imidazole
Prior art date
Application number
PCT/US2005/008904
Other languages
French (fr)
Other versions
WO2005099705A2 (en
Inventor
Stephen J Gardell
Original Assignee
Bayer Pharmaceuticals Corp
Stephen J Gardell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Stephen J Gardell filed Critical Bayer Pharmaceuticals Corp
Publication of WO2005099705A2 publication Critical patent/WO2005099705A2/en
Publication of WO2005099705A3 publication Critical patent/WO2005099705A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to imidazole compounds which are useful in promoting smoking cessation and maintaining abstinence.
PCT/US2005/008904 2004-03-24 2005-03-18 Preparation of imidazole derivatives and methods of use WO2005099705A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55592004P 2004-03-24 2004-03-24
US60/555,920 2004-03-24

Publications (2)

Publication Number Publication Date
WO2005099705A2 WO2005099705A2 (en) 2005-10-27
WO2005099705A3 true WO2005099705A3 (en) 2006-01-19

Family

ID=35150492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/008904 WO2005099705A2 (en) 2004-03-24 2005-03-18 Preparation of imidazole derivatives and methods of use

Country Status (1)

Country Link
WO (1) WO2005099705A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7106532B2 (en) 2016-11-07 2022-07-26 バイエル・アクチエンゲゼルシヤフト Substituted sulfonylamides for controlling pests

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2451629A (en) * 2007-08-06 2009-02-11 Univ Sheffield 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones
RU2705800C2 (en) 2014-06-06 2019-11-12 Рисерч Трайэнгл Инститьют Apelin receptor agonists (apj) and use thereof
CN107690281B (en) 2014-10-06 2020-11-17 弗特克斯药品有限公司 Cystic fibrosis transmembrane transduction modulator modulators
US10100059B2 (en) 2015-12-09 2018-10-16 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
AU2017233739A1 (en) 2016-03-15 2018-09-20 Bayer Cropscience Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests
PL3436446T3 (en) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
DK3519401T3 (en) 2016-09-30 2021-11-22 Vertex Pharma MODULE CYSTIC FIBROSET TRANSMEBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, TREATMENT METHODS AND MODULE MANUFACTURING METHOD
CN114507217A (en) * 2016-10-12 2022-05-17 三角研究所 Heterocyclic apelin receptor (APJ) agonists and uses thereof
IL294237A (en) 2016-12-09 2022-08-01 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AR112467A1 (en) 2017-08-02 2019-10-30 Vertex Pharma PROCESSES FOR PREPARING COMPOUNDS
IL273831B1 (en) 2017-10-19 2024-06-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
JP7245834B2 (en) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド A process for creating modulators of cystic fibrosis transmembrane conductance regulators
TWI810243B (en) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 Pharmaceutical compositions for treating cystic fibrosis
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2021089673A1 (en) 2019-11-07 2021-05-14 Bayer Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588739A (en) * 1984-03-02 1986-05-13 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US5021457A (en) * 1989-08-09 1991-06-04 Plough Inc. Method for aiding cessation of smoking
US5846974A (en) * 1995-08-15 1998-12-08 Eli Lilly And Company Method for treating substance abuse withdrawal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588739A (en) * 1984-03-02 1986-05-13 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US5021457A (en) * 1989-08-09 1991-06-04 Plough Inc. Method for aiding cessation of smoking
US5846974A (en) * 1995-08-15 1998-12-08 Eli Lilly And Company Method for treating substance abuse withdrawal

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7106532B2 (en) 2016-11-07 2022-07-26 バイエル・アクチエンゲゼルシヤフト Substituted sulfonylamides for controlling pests

Also Published As

Publication number Publication date
WO2005099705A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005099705A3 (en) Preparation of imidazole derivatives and methods of use
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2006050476A3 (en) Pyrimidine derivatives as ion channel modulators and methods of use
IL179754A0 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
WO2005112938A3 (en) Disalt inhibitors of il-12 production
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
HK1101284A1 (en) Derivatives of alkylpiperazine-and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
WO2004096798A3 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
IL177534A0 (en) Derivatives of piperidinylalkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors
TW200621721A (en) Methods of preparing indazole compounds
EP1863769A4 (en) Hsp90 inhibitors, methods of making and uses therefor
WO2008116139A3 (en) N-heterocyclic compounds useful as inhibitors of janus kinases
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
IL190477A0 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2006028810A3 (en) Method of wound healing using a2b adenosine receptor antagonists
WO2008061108A3 (en) Phthalazine derivatives
WO2006015178A3 (en) Growth factor encapsulation system for enhancing bone formation
WO2004110990A3 (en) Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
WO2005002525A3 (en) Cox-2 and faah inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase